| 1.195 -0.005 (-0.42%) | 04-24 11:33 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.47 | 1-year : | 1.6 |
| Resists | First : | 1.26 | Second : | 1.37 |
| Pivot price | 1.19  |
|||
| Supports | First : | 1.09 | Second : | 0.9 |
| MAs | MA(5) : | 1.17 |
MA(20) : | 1.2 |
| MA(100) : | 1.48 |
MA(250) : | 1.72 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 39.7 |
D(3) : | 32.4 |
| RSI | RSI(14): 44.5 | |||
| 52-week | High : | 3.54 | Low : | 1.09 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PLX ] has closed below upper band by 48.5%. Bollinger Bands are 17.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.24 - 1.25 | 1.25 - 1.25 |
| Low: | 1.15 - 1.15 | 1.15 - 1.16 |
| Close: | 1.19 - 1.2 | 1.2 - 1.21 |
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.
Fri, 15 Mar 2024
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2023 Earnings Call Transcript - Yahoo Finance
Thu, 14 Mar 2024
Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results - PR Newswire
Thu, 14 Mar 2024
Protalix BioTherapeutics, Inc. (PLX) Q4 2023 Earnings Call Transcript - Seeking Alpha
Fri, 23 Feb 2024
Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference - PR Newswire
Wed, 14 Feb 2024
PLX Stock Quote Price and Forecast - CNN
Wed, 31 Jan 2024
PLX: Biotech Stock Success: Top 3 Picks for Monthly Gains - StockNews.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 73 (M) |
| Shares Float | 65 (M) |
| Held by Insiders | 9.4 (%) |
| Held by Institutions | 13.4 (%) |
| Shares Short | 6,080 (K) |
| Shares Short P.Month | 5,680 (K) |
| EPS | 0.09 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.51 |
| Profit Margin | 16.6 % |
| Operating Margin | -18.3 % |
| Return on Assets (ttm) | 11.7 % |
| Return on Equity (ttm) | 79.4 % |
| Qtrly Rev. Growth | -27.2 % |
| Gross Profit (p.s.) | 0.38 |
| Sales Per Share | 0.87 |
| EBITDA (p.s.) | 0.2 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | 13.33 |
| PEG Ratio | 0.6 |
| Price to Book value | 2.3 |
| Price to Sales | 1.37 |
| Price to Cash Flow | -11.65 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|